Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2013 2
2014 3
2015 2
2016 6
2017 3
2018 4
2019 8
2020 9
2021 10
2022 6
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: rivellese f. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Ann Rheum Dis. 2023. PMID: 36357155
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes.
Zhang F, Jonsson AH, Nathan A, Millard N, Curtis M, Xiao Q, Gutierrez-Arcelus M, Apruzzese W, Watts GFM, Weisenfeld D, Nayar S, Rangel-Moreno J, Meednu N, Marks KE, Mantel I, Kang JB, Rumker L, Mears J, Slowikowski K, Weinand K, Orange DE, Geraldino-Pardilla L, Deane KD, Tabechian D, Ceponis A, Firestein GS, Maybury M, Sahbudin I, Ben-Artzi A, Mandelin AM 2nd, Nerviani A, Lewis MJ, Rivellese F, Pitzalis C, Hughes LB, Horowitz D, DiCarlo E, Gravallese EM, Boyce BF; Accelerating Medicines Partnership: RA/SLE Network; Moreland LW, Goodman SM, Perlman H, Holers VM, Liao KP, Filer A, Bykerk VP, Wei K, Rao DA, Donlin LT, Anolik JH, Brenner MB, Raychaudhuri S. Zhang F, et al. Among authors: rivellese f. Nature. 2023 Nov;623(7987):616-624. doi: 10.1038/s41586-023-06708-y. Epub 2023 Nov 8. Nature. 2023. PMID: 37938773 Free PMC article.
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, Lewis MJ, Pitzalis C; R4RA collaborative group. Rivellese F, et al. Nat Med. 2022 Jun;28(6):1256-1268. doi: 10.1038/s41591-022-01789-0. Epub 2022 May 19. Nat Med. 2022. PMID: 35589854 Free PMC article. Clinical Trial.
Reply.
Rivellese F, de Paulis A, Marone G, Pitzalis C, Toes RE. Rivellese F, et al. Arthritis Rheumatol. 2016 Mar;68(3):769-70. doi: 10.1002/art.39505. Arthritis Rheumatol. 2016. PMID: 26913844 No abstract available.
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes.
Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, Ramamoorthi N, John CR, Watson DS, Kummerfeld SK, Hands R, Riahi S, Rocher-Ros V, Rivellese F, Humby F, Kelly S, Bombardieri M, Ng N, DiCicco M, van der Heijde D, Landewé R, van der Helm-van Mil A, Cauli A, McInnes IB, Buckley CD, Choy E, Taylor PC, Townsend MJ, Pitzalis C. Lewis MJ, et al. Among authors: rivellese f. Cell Rep. 2019 Aug 27;28(9):2455-2470.e5. doi: 10.1016/j.celrep.2019.07.091. Cell Rep. 2019. PMID: 31461658 Free PMC article.
Editorial: Smoldering Inflammation in Cardio-Immune-Metabolic Disorders.
Varricchi G, Paolocci N, Rivellese F, Rengo G. Varricchi G, et al. Among authors: rivellese f. Front Physiol. 2021 Mar 19;12:651946. doi: 10.3389/fphys.2021.651946. eCollection 2021. Front Physiol. 2021. PMID: 33868019 Free PMC article. No abstract available.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Among authors: rivellese f. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.
Tertiary Lymphoid Organs in Rheumatoid Arthritis.
Rivellese F, Pontarini E, Pitzalis C. Rivellese F, et al. Curr Top Microbiol Immunol. 2020;426:119-141. doi: 10.1007/82_2020_216. Curr Top Microbiol Immunol. 2020. PMID: 32483659 Review.
Mast Cells in Early Rheumatoid Arthritis.
Rivellese F, Rossi FW, Galdiero MR, Pitzalis C, de Paulis A. Rivellese F, et al. Int J Mol Sci. 2019 Apr 25;20(8):2040. doi: 10.3390/ijms20082040. Int J Mol Sci. 2019. PMID: 31027208 Free PMC article. Review.
59 results